Key Highlights

  • Bio-Rad Laboratories shares are trading at $358.00 in Thursday's session, down 5.22%.
  • No company-specific negative has been identified.
  • The stock had run to near its 52-week high of $396.23 before the pullback.
  • A brokerage reiterated Outperform with a $390 target last week, citing a transformation that should support a 2027 sales recovery.

Rate Pressure Hits a High-Multiple Name Near Its Peak

Bio-Rad Laboratories (NYSE:BIO) is under pressure in a weak session for healthcare stocks, giving back ground after a run that left it near its 52-week high. The Hercules, California-based company makes life science research tools and clinical diagnostics products, and its shares are down about 5% at $358.00.

No company-specific negative has been identified. The 10-year Treasury Yield near 5.34%, a multi-decade high, tends to weigh on stocks with premium multiples, and Bio-Rad trades at a rich valuation relative to its earnings.

A Brokerage Sees the Transformation Paying Off in 2027

Last week a brokerage reiterated an Outperform rating with a $390 price target after meetings with management. It said the multi-year transformation, portfolio management, cost cuts and a pivot toward proven commercial M&A should support a 2027 sales recovery.

China Pressure and an Uneven Recovery Add Friction

Investors are also weighing pressure in China and an uneven recovery across life science customers. The stock trades within a 52-week range of $236.73 to $396.23, so Thursday's drop pulls it back from the upper end of that range.